From Akero Therapeutics 
Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero Therapeutics remarked, "I am delighted to welcome Scott Gangloff to Akero. His depth of experience leading drug manufacturing for both national and multi-national biopharmaceutical organizations enrich our company with an invaluable perspective during the late-stage clinical development of efruxifermin.  The entire leadership team looks forward to partnering with Scott to advance our commercialization and manufacturing strategy as we progress our Phase 3 trials and work toward providing meaningful treatment options to patients with MASH as quickly as possible."

Scott brings a strong . . .